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Background: Individuals with at-risk mental state for psychosis (ARMS) often suffer from depressive and anxiety
symptoms, which are clinically similar to the negative symptomatology described for psychosis. Thus, many
ARMS individuals are already being treated with antidepressant medication.
Objectives:To investigate clinical and structural differences between psychosis high-risk individualswith orwith-
out antidepressants.
Methods:We compared ARMS individuals currently receiving antidepressants (ARMS-AD; n = 18), ARMS indi-
viduals not receiving antidepressants (ARMS-nonAD; n = 31) and healthy subjects (HC; n = 24), in terms of
brain structure abnormalities, using voxel-based morphometry. We also performed region of interest analysis
for the hippocampus, anterior cingulate cortex, amygdala and precuneus.
Results: The ARMS-AD had higher ‘depression’ and lower ‘motor hyperactivity’ scores than the ARMS-nonAD.
Compared to HC, there was signiﬁcantly less GMV in the middle frontal gyrus in the whole ARMS cohort and
in the superior frontal gyrus in the ARMS-AD subgroup. Compared to ARMS-nonAD, the ARMS-AD group showed
more graymatter volume (GMV) in the left superior parietal lobe, but less GMV in the left hippocampus and the
right precuneus.We found a signiﬁcant negative correlation between attenuated negative symptoms and hippo-
campal volume in the whole ARMS cohort.
Conclusion:Reduced GMV in the hippocampus and precuneus is associatedwith short-term antidepressantmed-
ication andmore severe depressive symptoms. Hippocampal volume is further negatively correlated with atten-
uated negative psychotic symptoms. Longitudinal studies are needed to distinguish whether hippocampal
volume deﬁcits in the ARMS are related to attenuated negative psychotic symptoms or to antidepressant action.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The clinical high-risk state of psychosis (at-riskmental state, hereaf-
ter ARMS) is deﬁned by attenuated positive psychotic symptoms, genet-
ic liability and functional deterioration or brief and self-remitting
psychotic symptoms (Fusar-Poli et al., 2013; Yung et al., 1998). Howev-
er, affective symptoms, including depressive and anxiety symptoms, are
also highly prevalent in these individuals (Salokangas et al., 2012). A re-
cent meta-analysis, conducted in 1683 high-risk subjects, conﬁrmed), University of Basel, Wilhelm
(0)61 325 81 87; fax: +41
ardt).
. This is an open access article underthat the baseline prevalence of comorbid depressive and anxiety disor-
der is 41% and 15%, respectively (Fusar-Poli et al., 2014a). Depressive
and anxiety symptoms can precede the onset of attenuated positive
psychotic symptoms (Fusar-Poli et al., 2013). Some studies indicate
that co-occurrence of depressive disorders can predict subsequent tran-
sition to psychosis in ARMS individuals (Salokangas et al., 2012). How-
ever, other studies have not conﬁrmed this ﬁnding (Fusar-Poli et al.,
2014a). Additionally, a large study on 3349 twins suggests an associa-
tion between depressive and/or anxiety symptoms and psychosis-like
traits (schizotypy) and emphasizes a major role for genetics, especially
as regards positive symptoms (Macare et al., 2012). The comorbidity
of psychotic and depressive disorders in the ARMS population is associ-
atedwith speciﬁc psychopathological features at the time of the presen-
tation to high risk services and with low functional level (Fusar-Poli
et al., 2013). Because of these problems, clinical high-risk individualsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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in our previous study (Smieskova et al., 2012a)).
Negative psychotic symptoms are a major source of disability in the
psychosis spectrum and are refractory to any effective treatment
(Fusar-Poli et al., 2014b). Negative symptoms group into two factors,
one involving diminished expression of affect and alogia and the second
involving avolition, including anhedonia and asociality (Fusar-Poli et al.,
2014b). Antidepressantsmay have a potential beneﬁt for ARMS individ-
uals, as they may target their negative attenuated psychotic symptoms
(Cornblatt et al., 2007; Fusar-Poli et al., 2007). These studies indicate
that antidepressant treatments in ARMS individuals can impact their
longitudinal outcomes. However, it is not clear if these improvements
are associated with underlying neurobiological changes (Wood et al.,
2011).
Neuroimaging studies using magnetic resonance imaging (MRI)
have indicated that ARMS showed brain alterations in the prefrontal
(Borgwardt et al., 2006; Borgwardt et al., 2008; Koutsouleris et al.,
2009; Mechelli et al., 2011; Wood et al., 2010), cingulate (Fornito
et al., 2008; Koutsouleris et al., 2009), superior (Takahashi et al., 2009;
Takahashi et al., 2010) and medial temporal (Borgwardt et al., 2007b;
Tognin et al., 2014), insular (Smieskova et al., 2010) and cerebellar re-
gions when compared to healthy controls. Furthermore, ARMS individ-
uals with subsequent transition to psychosis showed volumetric
reductions in the prefrontal, insular and cingulate cortex compared to
those without transition (Smieskova et al., 2010).
Similar alterations were found in depressive disorders. Reductions in
graymatter volume (GMV) in the anterior cingulate gyrus, hippocampus,
amygdala (Koolschijn et al., 2009) and prefrontal cortex (Lorenzetti et al.,
2009) were associated with major depression. The only available study
directly testing the effect of comorbid depressive disorders on the neuro-
biology of ARMS uncovered a signiﬁcant impact on the anterior cingulate
region (Modinos et al., 2014). On the other hand, long-term antidepres-
sant medication can be neuroprotective and some studies have linked
the use of antidepressants to an increase in hippocampal volume in pa-
tients with major depressive disorder (Amico et al., 2011; Malykhin
et al., 2010). It has been shown that antidepressants increase hippocam-
pal neurogenesis (Anacker et al., 2011). Thus, both affective symptoms
(Baynes et al., 2000) and antidepressant medication (Kraus et al., 2014)
are known to impact brain structure.
In the present study, we addressed for the ﬁrst time the effect of an-
tidepressant treatment and attenuated negative psychotic symptoms
on the neurobiology of ARMS. Firstly, we hypothesized that ARMS indi-
viduals without current antidepressant treatment (ARMS-nonAD)
would manifest more severe attenuated negative symptoms than
ARMS subjects currently receiving antidepressants (ARMS-AD). Sec-
ondly, we hypothesized that ARMS-AD individuals would have in-
creased GMV in regions associated with depressive symptoms and/or
antidepressant medication (hippocampus, anterior cingulate gyrus,
amygdala and precuneus) compared to the ARMS-nonAD individuals.
Thirdly, we hypothesized that the volumetric abnormalities in gray
matter between ARMS-AD and ARMS-nonAD would be associated
with attenuated negative symptoms.
2. Materials and methods
2.1. Subjects
MRI data were collected within the framework of a research pro-
gram on the early detection of psychosis. The subjects were recruited
in our specialized clinic for the early detection of psychosis (FEPSY) at
the Psychiatric Outpatient Department, Psychiatric University Clinics
Basel, Switzerland (Riecher-Rössler et al., 2006).
The entire group of ARMS individuals (n = 49) conforms to Yung3s
criteria (Yung et al., 1998) and overlaps with previously published
data (Borgwardt et al., 2007a; Borgwardt et al., 2007b; Smieskova
et al., 2012a; Smieskova et al., 2012b). All the ARMS individuals wereantipsychotic-free andwere assessed prior to the neuroimaging session.
ARMS inclusion required one or more of the following:
(a) attenuated psychotic symptoms that do not reach full psychosis
threshold
(b) brief limited intermittent psychotic symptoms (lasting less than
a week with spontaneous remission)
(c) a ﬁrst degree relative with a psychotic disorder plus at least two
indicators of a clinical change, such as a marked decline in social
or occupational functioning.
We assessed the subjects using the Basel Screening Instrument for
Psychosis (BSIP) (Riecher-Rössler et al., 2008), the Brief Psychiatric
Rating Scale (BPRS) (Lukoff et al., 1986), the Scale for the Assessment
of Negative Symptoms (SANS) (Andreasen, 1989) and the Global
Assessment of Functioning (GAF) (Endicott et al., 1976). Attenuated
negative psychotic symptom severity was investigated with the cluster
‘negative symptoms’, calculated from the BPRS as a sum of blunted af-
fect, emotional withdrawal, and motor retardation (BPRS16, BPRS17
and BPRS18) (Fusar-Poli et al., 2014b; Velligan et al., 2005). Additionally,
we calculated ‘mood disturbance’ BPRS cluster as a sum of anxiety, de-
pression, suicidality and guilt (BPRS02, BPRS03, BPRS04 and BPRS05)
(Thomas et al., 2004), as well as depression (BPRS03) andmotor retarda-
tion (BPRS18) scores alone.We used these scores for stepwise regression
analysis with backward elimination.
In a second step, we divided the ARMS individuals into two sub-
groups, based on whether they were currently being treated with anti-
depressants (ARMS-AD, n = 18) or not (ARMS-nonAD, n = 31)
(Table 1). Antidepressantmedicationwithin the AD subgroup included:
ﬂuoxetine (SSRI; n = 2), escitalopram (SSRI; n = 5), sertraline (SSRI;
n = 1), mirtazapine [NaSSA (noradrenergic and speciﬁc serotonergic
antidepressant); n = 4], venlafaxine [SSNRI (selective serotonin–
norepinephrine reuptake inhibitor), n = 2], duloxetine (SSNRI;
n = 2), ﬂuoxetine plus trazodone [SSRI, SARI (serotonin antagonist and
reuptake inhibitor); n = 1] and St. John3s Wort (n = 1). Antidepressant
therapy had a mean duration of 50 ± 47 days (range 4–170 days). In
order to exclude possible biases through antipsychotic therapy, we con-
ﬁrmed that all individuals were antipsychotic-free. In addition, current
and previous psychotropic medication, alcohol, nicotine, cannabis, and
other illegal drug consumptionwere assessed using a semi-structured in-
terview, as adapted from the Drug and Alcohol Assessment Schedule of
the Early Psychosis Prevention and Intervention Centre (EPPIC).
Participants were excluded from the study if they presented
with a history of previous psychotic disorder, psychotic symptom-
atology secondary to an organic disorder, substance abuse, affective
psychosis, borderline personality disorder, age under 18 or over 40,
inadequate knowledge of the German language or IQ less than 70
(assessed by multiple-choice vocabulary intelligence test) (Lehrl
et al., 1995).
Healthy controls (n= 24) were from the same geographical area as
the other groups (Table 1). All participants provided written informed
consent. The study was approved by the local ethics committee.
2.2. Magnetic resonance imaging acquisition
For structural imaging, a whole brain 3D T1-weighted MPRAGE
(magnetization prepared rapid acquisition gradient) sequence was
applied using a 3 T magnetic resonance imaging scanner (Magnetom
Verio, Siemens Healthcare, Erlangen, Germany) and a 12-channel
radio frequency head coil. The acquisition was based on a sagittal
matrix of 256 × 256 × 176 and 1 × 1 × 1 mm3 isotropic spatial reso-
lution, with an inversion time of 1000 ms, repetition time of 2 s, echo
time of 3.4 ms, ﬂip angle of 8° and bandwidth of 200 Hz/pixel. All im-
ages were reviewed by trained neuroradiologists for radiological
abnormalities.
Table 1
Demographic and clinical data.
Characteristic ARMS-AD (n = 18) ARMS-nonAD (n = 31) HC (n = 24) Statistic Post hoc*
Gender M/F 14/4 24/7 10/14 χ2 = 9.231
p = 0.010
p = 0.977
Mean age (SD) 24.9 (5.0) 23.9 (4.9) 27.6 (4.6) F = 4.140
p = 0.020
p = 1.000
Handedness (left) 1 (5.6%) 2 (6.5%) 2 (8.3%) χ2 = 0.138
p = 0.933
Years of education (SD) 14.11 (3.45) 13.05 (2.59) 16.00 (2.80) F = 7.123
p = 0.002
p = 0.654
BPRS total score (SD) 41.56 (8.00) 39.04 (9.37) 24.54 (1.10) F = 36.971
p b 0.0001
p = 0.807
BPRS mood disturbance (SD) 11.22 (3.34) 9.35 (3.64) 4.50 (0.98) F = 30.746
p b 0.0001
p = 0.108
BPRS negative symptoms (SD) 6.33 (2.43) 5.36 (2.78) 3.00 (0.00) F = 13.699
p b 0.0001
p = 0.400
BPRS depression (SD) 4.17 (1.15) 3.23 (1.33) 1.13 (0.34) F = 47.456
p b 0.0001
p = 0.011**
BPRS motor hyperactivity (SD) 1.00 (0.00) 1.48 (0.89) 1.00 (0.00) F = 5.856
p = 0.005
p = 0.029**
SANS total score (SD) 22.00 (11.55) 17.88 (14.26) 0.00 (0.00) F = 25.721
p b 0.0001
p = 0.674
GAF (SD) 62.11 (10.92) 66.0 (12.38) 88.08 (4.15) F = 45.236
p b 0.0001
p = 0.583
Cigarettes smoked per day (SD) 12.83 (8.92) 5.31 (8.32) 3.25 (6.52) F = 8.105
p = 0.001
p = 0.006**
Current cannabis use 11 8 4 χ2 = 10.226
p = 0.006
p = 0.014**
Current alcohol use
No/moderate/
uncontrolled
3/10/5 7/21/3 1/21/2 χ2 = 8.125
p = 0.087
p = 0.253
Days on antidepressants (SD) 50 (47) None None
Range days 4–170
Abbreviations: ARMS, at-risk mental state individuals; ARMS-AD, ARMS with antidepressants; ARMS-nonAD, ARMS without antidepressants; BPRS, Brief Psychiatric Rating Scale; ‘BPRS
depression’, BPRS 3; ‘BPRS motor hyperactivity’, BPRS 23; ‘BPRS mood disturbance’, as a sum of anxiety, depression, suicidality and guilt (BPRS02, BPRS03, BPRS04 and BPRS05); ‘BPRS
negative symptoms’ as a sumof blunted affect, emotional withdrawal, andmotor retardation (BPRS16, BPRS17 and BPRS18); GAF, Global Assessment of Functioning; HC, healthy controls;
SANS, Scale for the Assessment of Negative Symptoms.
* Bonferroni correction (at p = 0.05) was calculated for post hoc analysis in SPSS 22.0. Only post hoc results between ARMS-AD and ARMS-nonAD groups are presented.
** Signiﬁcant results in post hoc analysis between ARMS-AD and ARMS-nonAD.
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Structural MRI data were analyzed using the voxel-basedmorphome-
try toolbox (VBM8, http://dbm.neuro.uni-jena.de/vbm8/), implemented
within SPM8 (Wellcome Department of Cognitive Neurology, London,
UK) and running onMatlab 7.11 (MathWorks, USA). All T1-weighted im-
ages were ﬁrst checked for scanner artifacts and anatomical abnormali-
ties. Images were then segmented into gray matter, white matter and
cerebrospinal ﬂuid using the adaptive maximum a posteriori technique
(in contrast to the classical use of a priori Tissue Probability Maps),
where local variations in the parameters aremodeled bymeans of slowly
varying spatial functions (Rajapakse et al., 1997). More accurate segmen-
tation can be achievedwith partial volume estimationof additionalmixed
tissue classes in every voxel. All images were DARTEL-normalized
(Diffeomorphic Anatomical Registration using Exponentiated Lie algebra;
Ashburner, 2007). The DARTEL template was derived from 550 healthy
controls as provided in MNI space. This method produces more accurate
results for registration and additional registration in MNI space was un-
necessary (Ashburner, 2007). Finally, sample homogeneity was reviewed
and all images were smoothed using an isotropic 8 mm full-width-at-half-
maximum (FWHM) Gaussian kernel (Shen and Sterr, 2013).
Group differences were explored using a one-way ANOVA. Since our
groups differed signiﬁcantly in gender and age, we introduced these
two variables as additional covariates of interest. Group comparisons in-
cludedARMS-ADversusARMS-nonADversus healthy controls. Brain re-
gion labeling was achieved using the Harvard–Oxford structural atlas
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases (Desikan et al., 2006)), in-
corporated within the FMRIB Software Library (FSL).Statistical signiﬁcance was assessed at a cluster level using a thresh-
old of p b 0.005 uncorrected (cluster-forming threshold); statistical in-
ference was then made at p b 0.05, adjusted to provide a family-wise
error (FWE) correction at the peak and cluster levels.
2.4. ROI analysis
On the basis of the previous evidence, we deﬁned 4 speciﬁc regions
of interest (ROIs) to test for differences in GMV between our two ARMS
groups: the bilateral hippocampus, (associated with greater risk of de-
pressive disorder; Amico et al., 2011; Vasconcelos et al., 2011), the ante-
rior cingulate gyrus (reported to be reduced during ongoing depression;
Amico et al., 2011; Koolschijn et al., 2009) and in co-morbid depression
in ARMS (Modinos et al., 2014); the amygdala (inconsistent changes in
depression; Koolschijn et al., 2009) and the precuneus (associated with
increased gray matter density after short antidepressant application in
HC; Kraus et al., 2014).
All the regions were individually deﬁned using theWake Forest Uni-
versity PickAtlas Toolbox (http://fmri.wfubmc.edu/software/PickAtlas).
For each region, a small volume correctionwas conducted using a 5mm
radius for the hippocampus (Amico et al., 2011; Vasconcelos et al.,
2011) and amygdala or a 10 mm radius for the precuneus and anterior
cingulate cortex (ACC) (Abutalebi et al., 2012; Amico et al., 2011).
Mean graymatter volume indiceswere extracted from these regions
using the Rex Toolbox (http://web.mit.edu/swg/software.htm) imple-
mented inMatlab 7.11. The analysiswas performed on region of interest
basis, with no conjunction mask, no scaling and extraction of the mean
within the predeﬁned ROI. The extracted values were used for a
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corrected family-wise error values were taken into consideration, in
order to avoid a type I error.
2.5. Statistical analysis of clinical variables
Clinical and socio-demographic differences were assessed using
one-way ANOVA and χ2-test. For post hoc analysis, the Bonferroni
correction was conducted. In addition, a stepwise regression analysis
with backward eliminationwas applied, to restrict correlating variables.
We included the BPRS total score and SANS total score; as well as the
BPRS clusters for ‘negative symptoms’ as a sum of blunted affect,
emotional withdrawal, and motor retardation (BPRS16, BPRS17 and
BPRS18); and ‘mood disturbance’ as a sum of anxiety, depression,
suicidality and guilt (BPRS02, BPRS03, BPRS04 and BPRS05); and the
single scores ‘depression’ (BPRS 3) and ‘motor hyperactivity’ (BPRS
23) (see Supplementary table). We applied outlier detection using
Cook3s Distance Test and no subject had to be excluded from regression
analysis. Still, we excluded one ARMS-nonAD individual due to missing
data in the BPRS 16, 17, and18necessary for calculating the cluster ‘neg-
ative symptoms’. We then performed a correlation with our signiﬁcant
clinical parameters from the stepwise regression. From the regions of
interest with signiﬁcant differences between ARMS-AD and ARMS-
nonAD (hippocampus and precuneus), we extracted the volumes and
used them in our in correlation calculations. The data were normally
distributed and we performed a series of two-tailed Pearson3s correc-
tion analyses with statistical threshold set at p b 0.05. All analyses
were performed using the Statistical Package for the Social Science
(SPSS, Version 22).
3. Results
3.1. Clinical and demographic characteristics
The ARMS-AD, ARMS-nonAD and HC showed signiﬁcant differences
in age at MRI scan (p = 0.02), gender (p = 0.01), years of education
(p = 0.002), smoking (p = 0.001), and cannabis (p = 0.006); but no
differences in alcohol consumption or handedness. Post hoc analysis
showed that smoking (p = 0.006) and cannabis consumption (p =
0.014) were signiﬁcantly more common in the ARMS-AD group than
in the ARMS-nonAD group (Table 1).
We observed signiﬁcant clinical differences between ARMS-AD,
ARMS-nonAD and HC in the total BPRS score (p b 0.0001), total SANS
score (p b 0.0001), GAF total score (p b 0.0001), BPRS cluster for ‘nega-
tive symptoms’ (p b 0.0001), BPRS ‘mood disturbance’ (p b 0.0001),
BPRS ‘depression’ score (p b 0.0001), and BPRS ‘motor hyperactivity’
score (p = 0.005). Post hoc analysis showed that the ARMS-AD had a
higher BPRS ‘depression’ score (p= 0.011) and less ‘motor hyperactivity’Table 2
Between group differences in gray matter volume.
Contrast Region p value
1. Whole brain analysis
p uncorr.
ARMS b HC Middle frontal gyrus 0.035
ARMS-AD b HC Superior frontal gyrus 0.028
ARMS-nonAD b ARMS-AD Left superior parietal lobe 0.023
2. Region of interest
p FWE-corr*
ARMS-AD b ARMS-nonAD Left hippocampus 0.029
ARMS-AD b ARMS-nonAD Right precuneus 0.042
The data presented here are from ANOVA of 3 included groups (ARMS-AD, ARMS-nonAD, HC)
There were no signiﬁcant differences in the following contrasts: ARMS N HC, ARMS-AD N HC, A
Abbreviations: ARMS, at riskmental state; ARMS-AD, ARMS subjects currently receiving antidep
healthy controls; KE, voxels per cluster; x y z, coordinates according to the Montreal Neurolog
Abbreviations: ARMS — at-risk mental state; ARMS-AD — ARMS with antidepressants; ARMS-n
* p b 0.0125 required.(p = 0.029) than the ARMS-nonAD (Table 1). The test of our a priori
deﬁned contrast in attenuated negative symptoms (BPRS cluster for ‘neg-
ative symptoms’) between ARMS-nonAD and ARMS-AD found no signif-
icant difference (p = 0.220).
3.2. Whole brain analysis
Compared to the HC, there was signiﬁcantly less GMV in the middle
frontal gyrus in the whole ARMS cohort, and in the superior frontal
gyrus in the ARMS-AD group (puncorr. b 0.05, Table 2).
The ARMS-nonAD group showed reduced GMV in the left superior
parietal lobe compared with the ARMS-AD group (puncorr. b 0.05,
Table 2).
3.3. Region of interest analyses
The ARMS-AD group had less GMV in the left hippocampus (Fig. 1)
and right precuneus than the ARMS-nonAD (pFWE-corr. b 0.05 after
small volume correction, Table 2). However, these results did not sur-
vive correction for multiple comparisons (p b 0.0125). No signiﬁcant
differences were found for the ACC and amygdala.
3.4. Correlation between ROI volumes and clinical parameters
We found a negative correlation between the hippocampal volume
and the BPRS ‘negative symptoms’ cluster, both in ARMS subjects
(r = −0.314, p = 0.030, Fig. 2) and in all our subjects, including the
HC (r =−0.293, p = 0.013).
There was no signiﬁcant correlation between the BPRS ‘negative
symptoms’ and the precuneus volume.
4. Discussion
In the present study, we addressed for the ﬁrst time the effect on
psychosis of antidepressant treatment and attenuated negative psy-
chotic symptoms in ARMS individuals.
Firstly, we have found no evidence for our ﬁrst hypothesis, that
ARMS individuals suffer more pronounced attenuated negative psy-
chotic symptoms if they have not been treated with antidepressants.
We found that ARMS-AD individuals had a higher depression score,
lower motor hyperactivity and smoked more cigarettes and marijuana
than the ARMS-nonAD individuals. The antidepressants that ARMS-AD
individuals were receiving differed in their mode of action – some
inhibited the reuptake of serotonin and/or noradrenaline, while others
enhanced the release of these monoamines (Andrade and Rao, 2010).
Moreover, the antidepressants may take weeks or longer to take effect
after dosage (Penn and Tracy, 2012). The duration of antidepressant
therapy in the ARMS-AD group varies from 4 to 170 days and thus theKE/radius z value x y z
790 3.59 −33 57 16
874 3.98 −33 57 18
944 4.33 −32 −40 45
5 mm 2.86 −18 −19 −17
10 mm 3.23 10 −78 51
at a threshold of p b 0.005 uncorrected across the whole brain.
RMS-nonAD vs. HC, and ARMS-nonAD N ARMS-AD.
ressants; ARMS-nonAD, ARMS individualswithout current antidepressantmedication;HC,
ical Institute.
onAD — ARMS without antidepressants; KE— voxels per cluster.
Fig. 1. Reductions in gray matter volume are associated with more severe depression. ARMS-AD individuals show less gray matter volume in the left hippocampus than ARMS-nonAD.
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and/or attenuated negative psychotic symptomsor of the already devel-
oped antidepressant effect of the medication. Hence, we cannot clearly
distinguish the extent towhich each of the two components contributes
to the current clinical state.
Secondly, we did not ﬁnd increased GMV in the regions associated
with depressive symptoms in those ARMS who were receiving antide-
pressants, compared to those without this medication. Thus we could
not conﬁrm our second hypothesis, but found GMV deﬁcits in the hip-
pocampus and precuneus only in the ARMS individuals currently re-
ceiving antidepressant medication.
Our third hypothesis is related to the volumetric abnormalities in
ARMS and their association with the attenuated negative symptoms;
we conﬁrmed this relationship in the hippocampus. We found a clear
negative correlation between the bilateral hippocampal volume and at-
tenuated negative symptoms in all ARMS individuals.
This corresponds to studies linking the hippocampuswith psychosis
(Jun et al., 2012). Previous studies similarly either found negative corre-
lations between the left hippocampal volume and negative symptoms
in schizophrenics (Rajarethinam et al., 2001), or at least a strong trend
in this direction (Brambilla et al., 2013). These ﬁndings underline the
role of the hippocampus in the pathophysiology of schizophrenia and
suggest speciﬁc associations between individual structures and both
the positive and negative symptoms of the illness (Kühn et al., 2012;Rajarethinam et al., 2001). Thus, our ﬁndings support the importance
of hippocampal structures as a region of interest in the early stage of
psychosis (Benetti et al., 2009; Fusar-Poli et al., 2012; Walter et al.,
2012).
Our ROI analysis demonstrated smaller GMV in the left hippocampus
in the ARMS-AD group than in the ARMS-nonAD group. The hippocam-
pus is involved in various psychiatric conditions, including major de-
pression and psychosis (Videbech and Ravnkilde, 2004; Walter et al.,
2012). Three meta-analyses have conﬁrmed signiﬁcant reductions in
the hippocampal volume in depression (Campbell et al., 2004; Cole
et al., 2011; Videbech and Ravnkilde, 2004). Furthermore, the total
number of depressive episodes was signiﬁcantly correlated to the re-
duction in the right hippocampal volume (Videbech and Ravnkilde,
2004). The left-hemispheric deﬁcits in hippocampal volumemay reﬂect
brain degeneration, as a consequence of chronic stress (Schmidt and
Duman, 2010). Recent data on antipsychotic-free ARMS have conﬁrmed
that vulnerability to psychosis may be associated with a signiﬁcant de-
crease in hippocampal volume (Fusar-Poli et al., 2012; Wood et al.,
2010).
In the right precuneus, we found less GMV in the ARMS-AD group
than in the ARMS-nonAD group. This is consistent with Grieve et al.
(Grieve et al., 2013), who found signiﬁcant reductions in the precuneus
volumes, along with several other structural changes in depression.
However, the direction of the effect is controversial. For example, a
Fig. 2. Attenuated negative psychotic symptoms are associated with hippocampal volume. ‘BPRS negative symptoms’ correlate negatively with the bilateral hippocampus volume in all
included ARMS subjects. The shaded area indicates the 95% CI of the ﬁtted regression line. ‘BPRS negative symptoms’ score is a sum of blunted affect, emotional withdrawal, and motor
retardation (BPRS16, BPRS17 and BPRS18). Hippocampal volume was extracted as mean gray matter volume in arbitrary units using Rex Toolbox.
235R. Bernasconi et al. / NeuroImage: Clinical 8 (2015) 230–237positive association was described between the volume of the precuneus
and the severity of depression (Kroes et al., 2011). It is well established
that intrusive imagery and increased self-focus, common in patients suf-
fering from depression, are regularly associated with higher depression
scores (Kroes et al., 2011). Since the precuneus is involved in visuospatial
processing, imagery and self-related processing (Kjaer et al., 2002;
Wenderoth et al., 2005), depression could in principle enhance its GMV.
We acknowledge the limitations of a cross-sectional design, which
precludes studying clinical and structural abnormalities within the
same group of ARMS before and after antidepressant medication. In
order to decide whether brain volumetric deﬁcits are related to distinct
depressive symptoms or to the antidepressant effect, longitudinal study
designs are needed. Secondly, other confounders, such as nicotine and
cannabis consumption, may have inﬂuenced our ﬁndings (higher con-
sumption in ARMS-AD individuals). Furthermore, the ARMS-nonAD
group shows more motor hyperactivity than the ARMS-AD group. This
could result from the early effect of the antidepressant medication or
from the sedative effect of cannabis or nicotine self-medication, which
was higher in the ARMS-AD group (Warburton, 1985). Cigarette use
may serve as an instrument to alleviate depressive symptoms, although
the role of cannabis consumption is unclear. We can only speculate that
the attenuated negative symptoms may drive cannabis consumption,
although this abuse may exacerbate the positive symptoms observed
(Gill et al., 2013). We are also aware that not all negative symptoms
are of hippocampal origin. In addition, the prescribed antidepressant
drugs have different afﬁnities to various synaptic receptors and there-
fore their effects on macroscopic structures and neurogenesis may
vary and also be associated with other brain regions. Likewise, differ-
ences in the duration of antidepressant therapy may affect their impact
on brain structure. Finally, relatively small sample groups are included,
which reduces the statistical power to detect any signiﬁcant effects.
5. Conclusion
Hippocampal volume was negatively associated with attenuated
negative psychotic symptoms in ARMS individuals. Surprisingly, ARMS
individuals without antidepressant medication did not suffer morepronounced attenuated negative psychotic symptoms. The short-term
antidepressantmedication in this study is more likely to be an indicator
of a more serious depressed state than to have a direct effect on attenu-
ated negative psychotic symptoms. These ﬁndings emphasize the im-
portance of comorbidity issues, especially in the context of depressive
and attenuated negative psychotic symptoms in clinical high-risk indi-
viduals and their functional outcomes.
Supplementarymaterial for this article can be found online at http://
dx.doi.org/10.1016/j.nicl.2015.04.016.References
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